Aspen

Aspen’s subsidiary finalized two interdependent agreements to acquire Sandoz China for up to €92.6 million. Simultaneously, AGI will dispose of commercialization rights for four anaesthetic products in the European Economic Area, receiving up to €55.5 million. The Acquisition’s upfront cash consideration will be funded by AGI through existing debt facilities. The completion of the Acquisition and Disposal is subject to the approval of the competition authority in China, with anticipated completion in Q2 2024, aiming to add approximately R1.8 billion of annual sales to the Aspen Group.
Click here to read the SENS